[Form 4] Artiva Biotherapeutics, Inc. Insider Trading Activity
Artiva Biotherapeutics insider Christopher Horan reported two dispositions of common stock tied to restricted stock unit vesting and tax withholding. On 05/15/2025 he had 1,341 shares withheld at an effective price of $2.13, reducing his direct ownership to 83,659 shares. On 08/15/2025 he had 3,577 shares withheld at $2.75, reducing his direct ownership to 80,082 shares. The filing identifies Horan as Chief Tech Operations Officer and was signed by an attorney-in-fact on 08/18/2025. The form states these share reductions "represent shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards," indicating these were not open-market sales but withholding transactions connected to equity compensation.
Il dirigente di Artiva Biotherapeutics, Christopher Horan, ha comunicato due riduzioni di azioni ordinarie legate al consolidamento di restricted stock unit e al relativo prelievo fiscale. Il 15/05/2025 sono state trattenute 1.341 azioni a un prezzo effettivo di $2,13, riducendo la sua detenzione diretta a 83.659 azioni. Il 15/08/2025 sono state trattenute 3.577 azioni a $2,75, portando la sua detenzione diretta a 80.082 azioni. Il deposito identifica Horan come Chief Tech Operations Officer ed è stato firmato da un procuratore il 18/08/2025. Il modulo dichiara che queste riduzioni di azioni "rappresentano azioni trattenute dall'Emittente per soddisfare obblighi fiscali sul reddito associati al consolidamento di award di restricted stock unit", indicando che non si trattava di vendite sul mercato aperto ma di operazioni di ritenuta connesse a compensi in equity.
El directivo de Artiva Biotherapeutics, Christopher Horan, informó dos disposiciones de acciones ordinarias vinculadas al vesting de unidades de acciones restringidas y a la retención fiscal. El 15/05/2025 se retuvieron 1.341 acciones a un precio efectivo de $2,13, reduciendo su propiedad directa a 83.659 acciones. El 15/08/2025 se retuvieron 3.577 acciones a $2,75, disminuyendo su propiedad directa a 80.082 acciones. La presentación identifica a Horan como Chief Tech Operations Officer y fue firmada por un apoderado el 18/08/2025. El formulario indica que estas reducciones de acciones "representan acciones retenidas por el Emisor para satisfacer obligaciones fiscales sobre la renta asociadas con el vesting de awards de restricted stock units", lo que señala que no fueron ventas en el mercado abierto sino retenciones relacionadas con la compensación basada en acciones.
Artiva Biotherapeutics의 임원 크리스토퍼 호란은 제한조건부주식단위(RSU) 베스팅 및 세금 원천징수와 관련된 보통주 처분 두 건을 보고했습니다. 2025-05-15에 유효단가 $2.13로 1,341주가 원천징수되어 그의 직접 보유주는 83,659주로 감소했습니다. 2025-08-15에 $2.75로 3,577주가 원천징수되어 그의 직접 보유주는 80,082주로 줄었습니다. 서류는 호란을 Chief Tech Operations Officer로 기재하고 있으며 2025-08-18에 대리인이 서명했습니다. 서식에는 이러한 주식 감소가 "제한조건부주식단위 보상 베스팅과 관련된 소득세 의무를 충족하기 위해 발행사가 원천징수한 주식"이라고 명시되어 있어, 이는 공개 시장에서의 매도가 아니라 주식 보상과 연계된 원천징수 거래였음을 나타냅니다.
Le dirigeant d'Artiva Biotherapeutics, Christopher Horan, a déclaré deux réductions d'actions ordinaires liées au vesting d'unités d'actions restreintes et au prélèvement fiscal. Le 15/05/2025, 1 341 actions ont été retenues à un prix effectif de 2,13 $, réduisant sa détention directe à 83 659 actions. Le 15/08/2025, 3 577 actions ont été retenues à 2,75 $, portant sa détention directe à 80 082 actions. le dépôt identifie Horan comme Chief Tech Operations Officer et a été signé par un mandataire le 18/08/2025. Le formulaire précise que ces réductions d'actions "représentent des actions retenues par l'Émetteur afin de satisfaire des obligations fiscales liées au revenu associées au vesting d'awards de restricted stock units", indiquant qu'il ne s'agissait pas de ventes sur le marché ouvert mais d'opérations de retenue liées à une rémunération en actions.
Der Insider von Artiva Biotherapeutics, Christopher Horan, meldete zwei Veräußerungen von Stammaktien im Zusammenhang mit dem Vesting von Restricted Stock Units und der Steuerabführung. Am 15.05.2025 wurden 1.341 Aktien zu einem effektiven Preis von $2,13 einbehalten, wodurch sein Direktbestand auf 83.659 Aktien sank. Am 15.08.2025 wurden 3.577 Aktien zu $2,75 einbehalten, wodurch sein Direktbestand auf 80.082 Aktien reduziert wurde. Die Meldung benennt Horan als Chief Tech Operations Officer und wurde am 18.08.2025 von einem Bevollmächtigten unterzeichnet. Das Formular erklärt, dass diese Aktienminderungen "Aktien darstellen, die vom Emittenten einbehalten wurden, um einkommensteuerliche Verpflichtungen im Zusammenhang mit dem Vesting von Restricted Stock Unit Awards zu erfüllen", was darauf hinweist, dass es sich nicht um Verkäufe am offenen Markt, sondern um Einbehaltungen im Zusammenhang mit Aktienvergütung handelte.
- Disclosure of tax-withholding on RSU vesting demonstrates compliance with Section 16 reporting requirements
- Transactions are administrative (withholding) rather than open-market sales, reducing likelihood of signaling liquidity-driven selling
- None.
Insights
TL;DR: Routine tax-withholding on RSU vesting, shows governance-compliant disclosure but no change to control.
The Form 4 discloses withholding of vested restricted stock units to satisfy income taxes, a standard practice that reduces reported beneficial ownership without indicating a voluntary divestiture. This preserves executive compensation mechanics while maintaining transparency. The reductions do not suggest a change in voting control or a disposition for liquidity. Documentation signed by an attorney-in-fact is common for administrative filings.
TL;DR: Non-market withholding lowers share count modestly; no evidence of opportunistic selling or material ownership shift.
The transactions are labeled as tax-withholding from RSU vesting, with 1,341 shares withheld at $2.13 and 3,577 shares withheld at $2.75, bringing direct holdings to 80,082 shares. For a public company, these amounts are minor relative to typical outstanding share counts and do not meet materiality thresholds for investor-impactful events. The reporting is consistent with Section 16 requirements.
Il dirigente di Artiva Biotherapeutics, Christopher Horan, ha comunicato due riduzioni di azioni ordinarie legate al consolidamento di restricted stock unit e al relativo prelievo fiscale. Il 15/05/2025 sono state trattenute 1.341 azioni a un prezzo effettivo di $2,13, riducendo la sua detenzione diretta a 83.659 azioni. Il 15/08/2025 sono state trattenute 3.577 azioni a $2,75, portando la sua detenzione diretta a 80.082 azioni. Il deposito identifica Horan come Chief Tech Operations Officer ed è stato firmato da un procuratore il 18/08/2025. Il modulo dichiara che queste riduzioni di azioni "rappresentano azioni trattenute dall'Emittente per soddisfare obblighi fiscali sul reddito associati al consolidamento di award di restricted stock unit", indicando che non si trattava di vendite sul mercato aperto ma di operazioni di ritenuta connesse a compensi in equity.
El directivo de Artiva Biotherapeutics, Christopher Horan, informó dos disposiciones de acciones ordinarias vinculadas al vesting de unidades de acciones restringidas y a la retención fiscal. El 15/05/2025 se retuvieron 1.341 acciones a un precio efectivo de $2,13, reduciendo su propiedad directa a 83.659 acciones. El 15/08/2025 se retuvieron 3.577 acciones a $2,75, disminuyendo su propiedad directa a 80.082 acciones. La presentación identifica a Horan como Chief Tech Operations Officer y fue firmada por un apoderado el 18/08/2025. El formulario indica que estas reducciones de acciones "representan acciones retenidas por el Emisor para satisfacer obligaciones fiscales sobre la renta asociadas con el vesting de awards de restricted stock units", lo que señala que no fueron ventas en el mercado abierto sino retenciones relacionadas con la compensación basada en acciones.
Artiva Biotherapeutics의 임원 크리스토퍼 호란은 제한조건부주식단위(RSU) 베스팅 및 세금 원천징수와 관련된 보통주 처분 두 건을 보고했습니다. 2025-05-15에 유효단가 $2.13로 1,341주가 원천징수되어 그의 직접 보유주는 83,659주로 감소했습니다. 2025-08-15에 $2.75로 3,577주가 원천징수되어 그의 직접 보유주는 80,082주로 줄었습니다. 서류는 호란을 Chief Tech Operations Officer로 기재하고 있으며 2025-08-18에 대리인이 서명했습니다. 서식에는 이러한 주식 감소가 "제한조건부주식단위 보상 베스팅과 관련된 소득세 의무를 충족하기 위해 발행사가 원천징수한 주식"이라고 명시되어 있어, 이는 공개 시장에서의 매도가 아니라 주식 보상과 연계된 원천징수 거래였음을 나타냅니다.
Le dirigeant d'Artiva Biotherapeutics, Christopher Horan, a déclaré deux réductions d'actions ordinaires liées au vesting d'unités d'actions restreintes et au prélèvement fiscal. Le 15/05/2025, 1 341 actions ont été retenues à un prix effectif de 2,13 $, réduisant sa détention directe à 83 659 actions. Le 15/08/2025, 3 577 actions ont été retenues à 2,75 $, portant sa détention directe à 80 082 actions. le dépôt identifie Horan comme Chief Tech Operations Officer et a été signé par un mandataire le 18/08/2025. Le formulaire précise que ces réductions d'actions "représentent des actions retenues par l'Émetteur afin de satisfaire des obligations fiscales liées au revenu associées au vesting d'awards de restricted stock units", indiquant qu'il ne s'agissait pas de ventes sur le marché ouvert mais d'opérations de retenue liées à une rémunération en actions.
Der Insider von Artiva Biotherapeutics, Christopher Horan, meldete zwei Veräußerungen von Stammaktien im Zusammenhang mit dem Vesting von Restricted Stock Units und der Steuerabführung. Am 15.05.2025 wurden 1.341 Aktien zu einem effektiven Preis von $2,13 einbehalten, wodurch sein Direktbestand auf 83.659 Aktien sank. Am 15.08.2025 wurden 3.577 Aktien zu $2,75 einbehalten, wodurch sein Direktbestand auf 80.082 Aktien reduziert wurde. Die Meldung benennt Horan als Chief Tech Operations Officer und wurde am 18.08.2025 von einem Bevollmächtigten unterzeichnet. Das Formular erklärt, dass diese Aktienminderungen "Aktien darstellen, die vom Emittenten einbehalten wurden, um einkommensteuerliche Verpflichtungen im Zusammenhang mit dem Vesting von Restricted Stock Unit Awards zu erfüllen", was darauf hinweist, dass es sich nicht um Verkäufe am offenen Markt, sondern um Einbehaltungen im Zusammenhang mit Aktienvergütung handelte.
FAQ
What did Christopher Horan report on the Form 4 for ARTV?
Do the reported transactions represent open-market sales of ARTV stock?
How many ARTV shares does Horan beneficially own after the transactions?
What is Christopher Horan's role at Artiva Biotherapeutics as listed on the Form 4?
Who signed the Form 4 submission for these transactions?
